Literature DB >> 16098423

Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.

Philippe Garot1, Thierry Lefèvre, Michael Savage, Yves Louvard, William R Bamlet, James T Willerson, Marie-Claude Morice, David R Holmes.   

Abstract

OBJECTIVES: The aim of this research was to determine the influence of bifurcation lesions on the outcome of patients undergoing percutaneous coronary intervention (PCI) in the recent era.
BACKGROUND: The treatment of bifurcation lesions by PCI has been associated with an increased complication rate. Whether recent improvements of interventional practice have translated into improved outcomes in this patient subgroup is unknown.
METHODS: The 11,482 patients enrolled in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) were stratified according to the presence (n = 1,412) or absence (n = 10,068) of at least one bifurcation lesion treated by PCI. Baseline characteristics and outcome of patients undergoing PCI for bifurcation lesions were compared to those of patients treated for nonbifurcation lesions.
RESULTS: Patients treated for bifurcation lesions were less likely to have prior myocardial infarction (MI), prior coronary artery bypass graft surgery, and had a higher proportion of current stable angina (p < 0.01 for all comparisons). Bifurcation lesions involved more frequently the left anterior descending coronary artery and were more complex (angulated, eccentric, ostial, and tortuous) than nonbifurcation lesions. Percutaneous coronary intervention of bifurcation lesions was characterized by less frequent stent implantation (71% vs. 80%); PCI of bifurcation lesions was associated with an increased rate of combined end point death/MI/target vessel revascularization (TVR) at nine months (18% vs. 15%, p = 0.002) because of increased rates of TVR (17% vs. 14%, p < 0.001), whereas death (1%) and MI (1%) were not different between groups.
CONCLUSIONS: Percutaneous coronary intervention of bifurcation lesions is associated with higher TVR at follow-up. However, the risk of death, MI, death/MI was similar in patients treated for bifurcation or nonbifurcation lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098423     DOI: 10.1016/j.jacc.2005.01.065

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Double guiding catheters for complex percutaneous coronary intervention.

Authors:  Shing-Hsien Chou; Chia-Pin Lin; Yen-Chen Lin; Chi-Tai Kuo; Ming-Shyan Lin; Chi-Jen Chang
Journal:  Tex Heart Inst J       Date:  2012

Review 2.  Recent perspective on coronary artery bifurcation interventions.

Authors:  Debabrata Dash
Journal:  Heart Asia       Date:  2014-02-14

Review 3.  Systematic Review and Network Meta-Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention.

Authors:  Dae Yong Park; Seokyung An; Neeraj Jolly; Steve Attanasio; Neha Yadav; Sunil Rao; Aviral Vij
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106

4.  Angiographic result of T-stenting with small protrusion using drug-eluting stents in the management of ischemic side branch: the ARTEMIS study.

Authors:  Man-Hong Jim; Eugene Brian Wu; Raymond Chi-Yan Fung; Andrew Kei-Yan Ng; Kai-Hang Yiu; Chung-Wah Siu; Hee-Hwa Ho
Journal:  Heart Vessels       Date:  2014-03-14       Impact factor: 2.037

5.  Long-term outcomes of rotational atherectomy in coronary bifurcation lesions.

Authors:  Yuxiang Dai; Atsutoshi Takagi; Hakuoh Konishi; Tetsuro Miyazaki; Hiroshi Masuda; Kazunori Shimada; Katsumi Miyauchi; Hiroyuki Daida
Journal:  Exp Ther Med       Date:  2015-10-19       Impact factor: 2.447

6.  Percutaneous coronary intervention for major bifurcation lesions using the simple approach: risk of myocardial infarction.

Authors:  Eram C Chaudhry; Kimberly P Dauerman; Christopher L Sarnoski; Colleen S Thomas; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2007-01-20       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.